Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|September 25, 2025
Assessment of Telisotuzumab Vedotin Drug-Drug Interaction Potential Using Physiologically-Based Pharmacokinetic Modeling and SimulationsMd Mahbubul Huq Riad, Priya Brunsdon, Rajeev Menon, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 26, 2026
Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing TumorsHeiko Babel, Priya Brunsdon, Benjamin Engelhardt, et al.
Therapeutic Drug Monitoring|June 17, 2016
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C InfectionPrajakta S Badri, Apurvasena Parikh, Eoin P Coakley, et al.
Leukemia & Lymphoma|August 12, 2017
Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphomaApurvasena Parikh, Sathej Gopalakrishnan, Kevin J Freise, et al.
Clinical Pharmacokinetics|February 21, 2018
Industry Perspective on Standardizing Food-Effect Studies for New Drug DevelopmentPatrick J Marroum, Silpa Nuthalapati, Apurvasena Parikh, et al.
Cancer Medicine|March 6, 2021
Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumorsYutaka Fujiwara, Hirotsugu Kenmotsu, Noboru Yamamoto, et al.
Clinical Pharmacology and Therapeutics|February 12, 2025
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B-Cell LymphomaTommy Li, Leonid Gibiansky, Apurvasena Parikh, et al.
Journal of Clinical Pharmacology|October 12, 2020
Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor AntagonistAkshanth R Polepally, Juki W Ng, Ahmed Hamed Salem, et al.
Clinical Pharmacokinetics|August 1, 2026
Exposure-Response Analyses to Inform the Optimal Epcoritamab Monotherapy Dosing Regimen in Relapsed or Refractory Follicular LymphomaMahipal Sinnollareddy, Kinjal Sanghavi, Leonid Gibiansky, et al.
Clinical Pharmacokinetics|December 21, 2024
Population Pharmacokinetics of Epcoritamab Following Subcutaneous Administration in Relapsed or Refractory B Cell Non-Hodgkin LymphomaTommy Li, Leonid Gibiansky, Apurvasena Parikh, et al.
Pageof 3